Zobrazeno 1 - 10
of 129
pro vyhledávání: ''
Autor:
Eva Ciruelos, Ingrid A. Mayer, Chong Ma, Sibylle Loibl, Dejan Juric, Albert Reising, Hope S. Rugo, Michelle Miller, Hiroji Iwata, Mario Campone, Pierfranco Conte, Fabrice Andre, Naveen Babbar, Monica Arnedos
Publikováno v:
Cancer Research. 81:PD2-06
Introduction: The PI3K pathway is often hyperactivated in cancer as a result of an altered PI3K isoform and/or loss of phosphatase and tensin homolog function. Approximately 40% of patients (pts) with hormone receptor-positive (HR+), human epidermal
Autor:
Emad A. Rakha, David M. Heery, Cíntia J. Monteiro, Kartikeya Bhardwaj, Nigel P. Mongan, Wilbert Zwart, Mansour Alsaleem, Steffi Oesterreich, Takaaki Fujii, Ian O. Ellis, Andrew R. Green, Stacey E. P. Joosten, Sasagu Kurozumi, Ken Shirabe, Simon J Johnston
Publikováno v:
Cancer Research. 81:PS6-11
Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancer and is typically ER+ and ERBB2 non-amplified. There is preclinical evidence that somatic ERBB2 mutation may provide an alternative and tractable mechanism for upregulation
Autor:
Jianying Zhou, Tejaswini P. Reddy, Hongbin Wang, Stacy L. Moulder, Wei Qian, Roberto R. Rosato, Jenny C. Chang, Helen Piwnica-Worms, Liliana Guzman
Publikováno v:
Cancer Research. 81:PS11-17
Metaplastic breast cancer (MpBC) is a rare subset accounting for less than 1% of all breast cancers. MpBC exhibits the worst prognosis in comparison to triple-negative breast cancer (TNBC) with a dismal poor survival rate in patients with metastatic
Autor:
Winfried R. Mulder, Lisa D. Eli, Neil T Conlon, Denis M. Collins, Suzanne J.C. van Gerwen, Alshad S. Lalani, Jeffrey J. Kooijman, Irmina Diala, John Crown, Guido J.R. Zaman
Publikováno v:
Cancer Research. 81:PS10-06
Introduction: Human epidermal growth factor 2 (HER2/ERBB2) is frequently amplified or mutated across various cancer types. The tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib are FDA-approved for the treatment of HER2-positive b
Autor:
Mariaelena Pierobon, Leslie S L Kim, Lance A. Liotta, Maren K Levin, Emanuel F. Petricoin, Elisa Baldelli, Joyce O'Shaughnessy
Publikováno v:
Cancer Research. 80:P4-10
Background: ER- HER2+ BC is comprised of a heterogeneous mix of intrinsic BC subtypes which have differential responsiveness to preop HER2-directed therapies combined with chemotherapy. Patients (pts) with ER- HER2+ BC whose disease progressed while
Autor:
Sri HariKrishna Vellanki, Mattia Cremona, Saraswati Sukumar, Alexander Casucci, Ciara Flynn, Yvonne E. Smith, Lance Hudson, Ann M. Hopkins, Kieran Brennan, Guannan Wang
Publikováno v:
Cancer Research. 80:P3-06
Background/Aim: Increased expression of the cell-cell adhesion molecule Junctional Adhesion Molecule-A (JAM-A) has been associated with poor prognosis and HER2 expression in patients with invasive ductal breast cancera,b. However, little is known abo
Autor:
Alex Pearson, Maria Teresa Herrera-Abreu, Alistair Ring, Paula Proszek, E Schuster, Ashutosh Nerurkar, David Gonzalez de Castro, Lina Yuan, Brian A Walker, Ben O'Leary, Javier Pascual, Marina Parton, Mike Hubank, Alicia Okines, Isaac Garcia-Murillas, Stephen R. D. Johnston, Elena Lopez-Knowles, Peter Osin, Mitch Dowsett, Rosalind J. Cutts, Monee K Shamsher, Hannah Bye, Sabri Jamal, Belinda Kingston, Charlotte Fribbens, Nicholas C. Turner
Publikováno v:
Clinical Cancer Research. 26:608-622
Purpose: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential to acquire mutations with
Autor:
I. Vanden Bempt, Ines Nevelsteen, Guiseppe Floris, J Goyens, H. Wildiers, K Punie, E Van Nieuwenhuysen, Patrick Neven, A Smeets, Ignace Vergote, S Vander Borght, Sileny Han
Publikováno v:
Cancer Research. 79:P3-08
Background: Clinical next-generation sequencing (NGS) has opened new perspectives on genome-driven therapy for metastatic breast cancer (MBC) through the identification of recurrent driver mutations. However, therapeutic relevance of the detection of
Publikováno v:
Cancer Research. 79:P5-11
Background: CDK4/6 inhibition combined with endocrine therapy is now a standard of care for advanced estrogen receptor (ER) positive breast cancer. Predictive genetic landscape and mechanisms of resistance to CDK4/6 inhibitors have not been described
Autor:
Akshata Udyavar, Junko Aimi, Ching-Wei Chang, Mark R. Lackner, Timothy R. Wilson, Heidi Savage, Jill M. Spoerke, Richard Bourgon, Anneleen Daemen, Joyce O'Shaughnessy
Publikováno v:
Molecular Cancer Research. 17:97-108
The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-posi